Study of the Vascular Effects of Serelaxin
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT01979614
- Locations
- 🇬🇧
Novartis Investigative Site, Leicester, United Kingdom
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT01979601
- Locations
- 🇺🇸
Novartis Investigative Site, Fargo, North Dakota, United States
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Other: Sham injection
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 252
- Registration Number
- NCT01976312
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh City, Vietnam
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
- Conditions
- Macular Edema Secondary to Branch Retinal Vein Occlusion
- Interventions
- Other: Sham injection
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 283
- Registration Number
- NCT01976338
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh City, Vietnam
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT01975701
- Locations
- 🇺🇸
University of California San Francisco Dept of Onc., San Francisco, California, United States
🇨🇭Novartis Investigative Site, Zürich, Switzerland
🇳🇱University Medical Center Utrecht, Utrecht, The Netherlands, Netherlands
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
- Conditions
- Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 349
- Registration Number
- NCT01972789
- Locations
- 🇦🇺
Novartis Investigative Site, Nedlands, Western Australia, Australia
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01972776
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01968915
- Locations
- 🇯🇵
Novartis Investigative Site, Kobe-city, Hyogo, Japan
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Drug: INC280Drug: Placebo
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01964235
- Locations
- 🇺🇸
Research Medical Center Onc Dept, Kansas City, Missouri, United States
🇨🇭Novartis Investigative Site, Genève, Switzerland
🇺🇸Massachusetts General Hospital Mass General Hospital, Boston, Massachusetts, United States
Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
- Conditions
- Psoriasis
- Interventions
- Biological: Secukinumab (AIN457)
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 235
- Registration Number
- NCT01961609
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom